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ABSTRACT The barbiturate pentobarbital binds to g-aminobutyric acid type A (GABAA) receptors, and this interaction plays an
important role in the anesthetic action of this drug. Depending on its concentration, pentobarbital can potentiate (~10–100 mM),
activate (~100–800 mM), or block (~1–10 mM) the channel, but the mechanisms underlying these three distinct actions are poorly
understood. To investigate the drug-induced structural rearrangements in the GABAA receptor, we labeled cysteine mutant
receptors expressed in Xenopus oocytes with the sulfhydryl-reactive, environmentally sensitive ﬂuorescent probe tetramethyl-
rhodamine-6-maleimide (TMRM). We then used combined voltage clamp and ﬂuorometry to monitor pentobarbital-induced
channel activity and local protein movements simultaneously in real time. High concentrations of pentobarbital induced
a decrease in TMRM ﬂuorescence (FTMRM) of labels tethered to two residues in the extracellular domain (a1L127C and
b2L125C) that have been shown previously to produce an increase in FTMRM in response to GABA. Label at b2K274C in the
extracellular end of the M2 transmembrane helix reported a small but signiﬁcant FTMRM increase during application of low
modulating pentobarbital concentrations, and it showed a much greater FTMRM increase at higher concentrations. In contrast,
GABA decreased FTMRM at this site. These results indicate that GABA and pentobarbital induce different structural rearrange-
ments in the receptor, and thus activate the receptor by different mechanisms. Labels at a1L127C and b2K274C change their
ﬂuorescence by substantial amounts during channel blockade by pentobarbital. In contrast, picrotoxin blockade produces no
change in FTMRM at these sites, and the pattern of FTMRM signals elicited by the antagonist SR95531 differs from that produced
by other antagonists. Thus, with either channel block by antagonists or activation by agonists, the structural changes in the
GABAA receptor protein differ during transitions that are functionally equivalent.INTRODUCTION
Many drugs with anesthetic, hypnotic, sedative, convulsant,
and anticonvulsant actions act upon g-aminobutyric acid
type A (GABAA) receptors. These drugs belong to a number
of distinct chemical classes that include barbiturates, neuro-
steroids, and benzodiazepines (1,2). In addition to the prin-
cipal agonist binding site to which GABA binds, the
GABAA receptor has structurally distinct binding sites for
many of its other ligands. The structural basis for the diverse
actions of different classes of drugs on the same molecular
target represents a major challenge in the investigation of
structure-function relationships in the GABAA receptor.
The barbiturate pentobarbital binds to GABAA receptors
and, depending on its concentration, modifies the function
of this protein in three distinct ways. Below ~100 mM, pento-
barbital has little or no effect on its own, but it potentiates
channel activity induced by subsaturating concentrations of
GABA (3–5). Intermediate concentrations of pentobarbital
(~100 mM–1 mM) act as a receptor agonist to gate the
channel in the absence of GABA (6). Above ~1 mM, pento-
barbital becomes inhibitory and blocks current through the
channel (6–8). The structural mechanisms underlying these
different actions are not well understood.
GABAA receptors are members of the Cys-loop family of
ligand-gated ion channels. These heteropentamers are
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gous subunits (9,10). Each subunit contains an extracellular
N-terminus of ~200 amino acids, 4 transmembrane a-helices
(M1–M4), and a short extracellular C-terminus. GABA
binds to sites within pockets formed by the interfaces of
the N-termini of adjacent a- and b-subunits (11). Barbitu-
rates such as pentobarbital are thought to bind to a completely
different site, possibly formed by parts of M1, M2, and M3
of the b-subunits (12–14). Indeed, barbiturates can directly
gate channels formed by b-subunit homomeric receptors,
but GABA cannot (15,16). Thus, b-subunits harbor
structural elements sufficient for barbiturate binding, but
activation by GABA requires additional elements. When
pentobarbital acts as an agonist, the structural changes in
the GABAA receptor resemble those induced by GABA in
an important respect; the channels have the same unitary
conductance (8,17). This finding raises an interesting
question about how GABA and pentobarbital induce similar
activated states by binding to different sites.
Simultaneous electrophysiology and site-specific fluorom-
etry have shown that labels tethered to residues in the
N-terminal domains of GABAA receptors undergo changes
in their environment in response to GABA and other ligands
(18,19). Similar experiments in the related nicotinic acetyl-
choline (20) and glycine receptors (21) showed that two
different agonists induce distinct protein movements during
activation. In this study, we used this approach to investigate
the molecular rearrangements of the GABAA receptor
doi: 10.1016/j.bpj.2008.09.037
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and upper M2 that undergo distinct structural changes de-
pending on whether the receptor binds GABA or pentobar-
bital; these changes also reveal differences in the molecular
mechanisms of action of these two ligands.
MATERIALS AND METHODS
Molecular biology and oocyte expression
Individual cysteine substitutions were made by recombinant polymerase
chain reaction-driven site-directed mutagenesis (as described in the works
by Muroi et al. (19) and Boileau et al. (22)) in DNA encoding rat
GABAA a1-subunit (E122C, L127C, K278C), b2-subunit (P120C, L125C,
K274C), and g2-subunit (N135C, L140C, K289C) in the pGH19 vector
(23). In this work, the key sites studied in depth are highlighted in Fig. 1 B.
The mutations were confirmed by DNA sequencing. Capped mRNA was
prepared using the mMessage mMachine in vitro transcription kit (Ambion,
Austin, TX). Oocytes were surgically isolated from anesthetized adult
female Xenopus laevis and defolliculated after agitation in 1 mg/mL collage-
nase (Roche, Basel, Switzerland) in zero Ca2þ-ND96 (96 mM NaCl, 2 mM
KCl, 1 mM MgCl2, 5 mM HEPES, pH 7.7). Before and after injection, the
oocytes were stored in ND96 (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1
mM MgCl2, 5 mM HEPES, pH 7.4) supplemented with 100 mg/mL genta-
micin and 100 mg/mL bovine serum albumin (Fisher, Pittsburgh, PA).
Oocytes were injected 24–48 h after surgery with ~30 nL of an injection
cocktail containing a/b-subunit encoding mRNA in a 1:1 ratio (6.7–18
ng/subunit) or a/b/g-subunit encoding mRNA in a 1:1:10 ratio (4.5–27
ng/subunit). Injected oocytes were incubated at 18C for 3–10 days before
the experiments.
Fluorophore labeling
Oocytes were incubated in 10 mM tetramethylrhodamine-6-maleimide
(TMRM; Invitrogen, Carlsbad, CA) in ND96 on ice for 30 min in the
dark. They were then washed with ND96 and used for recording immedi-
ately or stored on ice for use within 3 h. A 10 mM stock of TMRM was
prepared in dimethyl sulfoxide and stored at 80C.
Two-electrode voltage clamp
All recordings were performed at room temperature in a darkened room.
Oocytes were clamped at 80 mV with an OC-725C Oocyte Clamp ampli-
fier (Warner Instruments, Hamden, CT). The oocyte was perfused continu-
ously in a ~200 mL chamber with ND96 (~5 mL/min). Glass micropipettes
were filled with 3 M KCl and had resistances of 0.2–2.0 MU. Fluorescence
and current signals were read into a personal computer running Clampex 8
software (Molecular Devices, Sunnyvale, CA).
Substituted cysteines were checked for reactivity with TMRM using
a functional assay in which current responses to ~EC50 GABA were
compared before and after 5-min treatments with 100–500 mM TMRM in
ND96. A successful cysteine modification resulted in a change of > 20%
in current amplitude. Cysteine mutant-expressing oocytes incubated with
TMRM displaying significant changes in fluorescence (see below) compared
to wild-type upon ligand addition were also assumed to have been success-
fully modified. Incorporation of the g2-subunit was confirmed by testing for
potentiation of responses to low GABA concentrations by flurazepam (22).
Concentration-response curves were analyzed as described previously
(19). Plots of fluorescence change versus concentration were fitted to the
Hill equation as follows:
y ¼ Fmax

xn=ECn50 þ xn

;
where Fmax is the maximum fluorescence change, x is the ligand concentra-
tion, n is the Hill coefficient, and EC50 is the ligand concentration producing
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ware (MicroCal, Northampton, MA) or Prism software (GraphPad, San
Diego, CA).
For studies of the concentration dependence of block by pentobarbital, the
extent of block was calculated from the peak ‘‘tail’’ current, determined by
extrapolating the exponential decay (fitted with Clampfit 8; Molecular
Devices) of the off-response (as the drug was removed) back to the start
of drug removal (see Fig. 7, insets).
Simultaneous current and ﬂuorescence recording
Parallel measurements of fluorescence and current were conducted as
described previously (19). In brief, illumination from a 100 W halogen lamp
was filtered through an excitation filter (535/50 nm excitation) and reflected
with a 565 dichroic mirror onto the preparation through a Zeiss  10 0.50
NA objective (Carl Zeiss, Thornwood, NY). Fluorescent light passed through
a 610/75 nm emission filter and was measured with a Hamamatsu (Bridge-
water, NJ) photomultiplier tube. An electronic shutter controlled illumination.
Structural modeling
A homology model based on the crystal structure of the Lymnaea acetylcho-
line-binding protein (24) for the extracellular domain and the 4 A˚ structure of
the Torpedo nicotine acetylcholine receptor (25) for the transmembrane
domain was constructed for the rat GABAA receptor as described previously
(26). In brief, amino acid sequences of the GABAA receptor were aligned
and threaded onto the parent structures and then energy minimized with
SYBYL software (Tripos, St. Louis, MO). The two domains were then phys-
ically docked and again energy minimized in SYBYL.
The GABAA receptor model images in Fig. 1 were developed using the
PyMOL Molecular Graphics System (DeLano Scientific, Palo Alto, CA).
Statistical analysis
A one-way analysis of variance (ANOVA) was performed using Prism soft-
ware (GraphPad) to compare fluorescence changes induced by similar drug
concentration (e.g., activating pentobarbital or EC90–99 GABA) between
mutants and controls (wild-type receptors). The post hoc Dunnett’s test
was performed after the ANOVA. The error bars in the graphs represent
mean5 SE for nR 3 trials.
RESULTS
Previous studies of the extracellular domain of the GABAA
receptor demonstrated that fluorescent labels attached to
residues E122C and L127C of the a1-subunit and to the
homologous residues of the b2-subunit (P120C and
L125C, respectively) report changes in their chemical envi-
ronments when either GABA or the competitive antagonist
SR95531 bind to the receptor (19). The homologous residues
of the g2-subunit (residues N135C and L140C, respectively)
were also examined. Substituting a cysteine at g2L140 had
a dominant negative effect and suppressed the formation of
functional GABAA receptors. a1b2g2N135C expressed
well; when labeled with TMRM, however, this receptor
showed no changes in fluorescence (FTMRM) in response to
GABA or SR95531. Labeling of this receptor was confirmed
by showing a change in its current response, and so this site
does not appear to be sensitive to the binding of these
ligands. We used TMRM labeling to determine whether
these same extracellular domain sites that reported changes
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FIGURE 1 Three TMRM-labeled sites in the GABAA
receptor showing fluorescence changes in response to
pentobarbital. Structural model of the heteropentameric
GABAA receptor from an extracellular, top-down view
(A) and from a side view at the GABA binding interface
(B). Labels indicate subunit subtypes. Residues at sites
reporting changes in fluorescence in the b2-subunit are
shown as green and in the a1-subunit are shown as red.
Fluorescence changes are summarized in Table 1 and
Fig. 6.in response to GABA and SR95531 would also report
changes in response to pentobarbital at modulating, acti-
vating, and blocking concentrations. We also investigated
FTMRM signals from labels at b2K274 and aligned residues
in other subunits. Key sites in the N-terminus and upper
M2 are indicated in Fig. 1.
The sites tested with pentobarbital in simultaneous voltage
clamp and fluorometry recording are indicated in Table 1. In
all of these labeled receptors, GABA or pentobarbital gener-
ally elicited currents in the range of 10–25 mA, indicating
these mutants expressed well. At most of these sites, pento-
barbital elicited no significant FTMRM signal. Residues at
which labels showed a fluorescence change in response to
10 mM pentobarbital in either a1b2 or a1b2g2 receptors are
indicated in Table 1 with bold type.
The extracellular domain of the GABAA receptor
Modulating concentrations of pentobarbital (<100 mM)
applied in the absence of GABA induced little or no current
response and failed to elicit statistically significant changes
in FTMRM at any of the sites in the extracellular domain
(see Fig. 6). We know that pentobarbital binds to the
GABAA receptor at this concentration because the same
low concentrations of pentobarbital elicited a fluorescence
change in TMRM-b2K274C (data presented below). Further-
more, previous studies have shown that potentiating pento-
barbital concentrations alter the accessibilities of cysteines
introduced at the GABA binding pocket to thiol-reactive
reagents (27). Thus, in the absence of GABA, occupation
of a high-affinity modulating site on the GABAA receptor
by pentobarbital produces no detectable structural changes
in the vicinity of residues a1E122, a1L127, b2P120, or
b2L125, whereas these locations undergo clear changes in
response to GABA and, in some cases, to SR95531 as well
(19). We tested pentobarbital concentrations of 300 mM,
800 mM, and 10 mM and observed no change in fluorescence
in TMRM-g2N135C.
To investigate GABAA receptor activation by pentobar-
bital, we tested concentrations in the range of 300–800 mM.
These intermediate concentrations elicited small fluores-
cence decreases in some of these extracellular domainlabels (Fig. 2). Activating concentrations of pentobarbital
elicit GABAA receptor current while showing little or no
evidence of channel block (as judged by tail current; see
below). In receptors either lacking (a1b2, Fig. 2 A) or con-
taining (a1b2g2, Fig. 2 B) a g2-subunit, TMRM-a1L127C
showed a fluorescence increase in response to GABA and
a fluorescence decrease in response to pentobarbital. The
opposite sign of the FTMRM changes produced by these
two agonists suggest that GABA and pentobarbital induce
different molecular rearrangements in the extracellular
domain. However, a more thorough analysis of the concen-
tration dependence of pentobarbital-induced fluorescence
changes presented below indicates that the fluorescence
changes induced by intermediate, activating concentrations
of pentobarbital reflect a small amount of blocking action.
We will return to this issue after presenting additional data.
TMRM-b2L125C reported no change in fluorescence in
response to pentobarbital, regardless of whether a g2-subunit
was present (Fig. 2, C and D). TMRM-b2L125C did show
a fluorescence change in response to GABA when the
TABLE 1 TMRM ﬂuorescence changes
Label site
a1b2g2 a1b2
PB GABA PB GABA
a1E122 – Y – Y
a1L127 – [ Y [
a1K278 – – nt nt
b2P120 – – – –*
b2L125 – – Y –*
b2K274 [ Y [ –
g2N135 – – – –
g2K289 – – nt nt
Fluorescence increases (upward arrow) and decreases (downward arrow)
elicited by 10 mM pentobarbital (PB) and EC90–99 GABA. ‘‘–‘‘ denotes
no significant change in fluorescence. ‘‘nt’’ denotes not tested. Label sites
in bold type denote sites at which PB elicited fluorescence changes in either
a1b2g2 or a1b2 receptors.
*In a previous report (19), a label at b2P120 showed a fluorescence decrease,
and a label at b2L125 showed a fluorescence increase. These changes were
statistically significant compared to control recordings in wild-type receptors
(p< 0.05) using the t-test. However, when the ANOVA technique was used
to analyze the data set in this study, these changes were no longer significant.
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800 μM PB
C αβL125C
80 μM GABA
10 μA10 sec
0.5 %
1%
800 μM PB
30 mM GABA
5 sec
B αL127Cβγ
15 μA
I
ΔF
D αβL125Cγ
80 μM GABA
800 μM PB
0.3 %
5 sec 5 μA
5 %
500 μM PB
30 mM GABA
5 sec 5 μA
A αL127Cβ
I
ΔF
FIGURE 2 Current and fluorescence responses of
N-terminus labels to GABA and activating concentrations
of pentobarbital. Simultaneous current (top) and fluores-
cence (bottom) changes induced by EC90–99 GABA
(black traces: 30 mM in A and B; 80 mM in C and D)
and an activating pentobarbital concentration (gray traces:
500–800 mM). (A) TMRM-a1L127Cb2 receptors, (B)
TMRM-a1L127Cb2g2 receptors, (C) TMRM-a1b2L125C
receptors, and (D) TMRM-a1b2L125Cg2 receptors.
502 Muroi et al.g2-subunit was absent (as evidenced in a comparison
between panels C and D in Fig. 2). The significance of this
change cannot be assessed unambiguously. In a previous
study (19), we found this change to be significant according
to the t-test; in this work, however, ANOVA with a larger
data set (additional mutants) indicated that this change was
not statistically significant. In the same manner, the
TMRM-a1E122C and TMRM-b2P120C fluorescence also
did not change in response to activating concentrations of
pentobarbital (data not shown), but we previously reported
that these sites change their fluorescence in response to
GABA (19). Furthermore, GABA and SR95531 produced
fluorescence changes opposite in sign in both TMRM-
a1E122C and TMRM-a1L127C (19). Thus, depending on
the ligand and the site, labels in this region reported
increases, decreases, or no change in fluorescence, indicating
that this part of the GABAA receptor undergoes different
conformational rearrangements in response to the binding
of different ligands.
Above a concentration of 1 mM, pentobarbital blocks the
GABAA receptor channel by an unknown mechanism (7,28).
The peak current elicited by a concentration of 10 mM pento-
barbital was lower than that elicited by 300–800 mM. Upon
drug removal, the current increased transiently before return-
ing to baseline (Fig. 3). This ‘‘tail’’ current indicates that
pentobarbital dissociates from a blocking site on the receptor
more rapidly than from an activation site. At a concentration
Biophysical Journal 96(2) 499–509of 10 mM, pentobarbital produced prominent fluorescence
changes in TMRM-a1L127C and TMRM-b2L125C, which
were considerably greater than those elicited by activating
concentrations (as evidenced by a comparison of Fig. 3
with Fig. 2). Upon pentobarbital removal, FTMRM decayed
rapidly, but the current increased as the tail appeared. This
divergence of the current and fluorescence upon drug
removal contrasts sharply with the more similar time courses
of changes in these two signals as the drug was applied. The
tail current reached a peak close to the time when the fluores-
cence returned to baseline. This finding suggests that the
FTMRM change induced by pentobarbital reflects blockade
rather than receptor activation and channel opening. As
with activating concentrations, blocking concentrations of
pentobarbital only produced fluorescence changes in labels
at the two aligned residues a1L127C and b2L125C. Labels
at the other sites in the extracellular domain tested in this
study failed to show fluorescence changes with any pento-
barbital concentration (Table 1).
The upper end of M2
The extracellular end of M2 (the pore-lining helix) harbors
a conserved lysine residue (position 240) implicated in the
transduction of binding to gating in the GABAA receptor
(29–31). We therefore used TMRM labeling to investigate
structural changes induced by pentobarbital and other
ligands. The mutant b2K274C was incorporated into func-
tional receptors either with or without a g2-subunit. Acti-
vating concentrations of pentobarbital (300–800 mM) elicited
fluorescence changes from a label at this site (Fig. 4), but
labels at the aligned positions in the other subunits (a1K278
and g2K289) showed no significant changes (Table 1). As
with the label at a1L127C in the extracellular domain, the
fluorescence change elicited by GABA in the TMRM-
a1b2K274Cg2 receptors was opposite in sign to that elicited
by pentobarbital (Fig. 4 A).
In contrast to labels in the extracellular domain, TMRM-
b2K274C (in a1b2 receptors) produced a change in fluores-
cence even in response to a low, potentiating concentration
(60 mM) of pentobarbital (Fig. 4 B). Because this concentra-
tion failed to elicit detectable current, these fluorescence
signals reflect an electrically silent event in the GABAA
receptor protein. This result was specific for a1b2 receptors;
modulating concentrations of pentobarbital failed to elicit
a statistically significant fluorescence change in TMRM-
a1b2K274Cg2 receptors.
As in oocytes expressing receptors with labels in the
N-terminus (Fig. 3), blocking concentrations of pentobar-
bital (>1 mM) elicited current responses in TMRM-
a1b2K274Cg2 and TMRM-a1b2K274C receptors with tail
1 %
10 mM PB
5 sec
5 μA
A αL127Cβ
0.2 %
5 sec
B αL127Cβγ
5 μA
I
I
ΔF
ΔF
C αβL125C
5 μA
0.5 %
D αβL125Cγ
5 sec
10 mM PB
10 mM PB
0.3 %
5 μA
5 sec
10 mM PB
FIGURE 3 Current (top) and fluorescence (bottom)
responses of N-terminal labels to blocking concentrations
of pentobarbital (10 mM). (A) TMRM-a1L127Cb2 recep-
tors, (B) TMRM-a1L127Cb2g2 receptors, (C) TMRM-
a1b2L125C receptors, and (D) TMRM-a1b2L125C g2
receptors. Note prominent tail currents upon pentobarbital
removal.
I
ΔF
500 μM PB
800 μM PB
60 μM PB
1 mM GABA
A B
5 sec
1% 1%
αβK274Cγ αβK274C
I
ΔF
5 μA
5 μA
5 sec
FIGURE 4 Current (top) and fluorescence (bottom)
responses of labels in M2. (A) Activating concentrations
of pentobarbital (gray traces) and GABA (black traces)
on TMRM-a1b2K274Cg2. (B) Activating (black traces)
and modulating (gray traces) concentrations of pentobar-
bital on TMRM-a1b2K274C receptors.
Biophysical Journal 96(2) 499–509
Structural Changes in the GABAA Receptor 503
currents characteristic of receptor blockade (Fig. 5). With
this high concentration of pentobarbital, the onset of the
fluorescence and current responses moved roughly in
parallel upon drug application, but the fluorescence decayed
more rapidly upon drug removal. In summary, TMRM-
a1b2K274C receptors reported a fluorescence increase with
all pentobarbital concentrations tested, but the magnitude
varied depending on the concentration used.
Concentration dependence of pentobarbital
actions
Fig. 6 summarizes the FTMRM signals elicited by different
pentobarbital concentrations from labels on residues
a1L127C, b2L125C, and b2K274C in a1b2 and a1b2g2
receptors. Fluorescence changes elicited by GABA are also
presented; these changes include results for GABA on
a1L127C and b2L125C that were found in our previous
work (19). Fig. 6 illustrates the contrasts in structural
changes induced by potentiating, activating, and blocking
pentobarbital concentrations; the relationship between these
fluorescence signals and the distinct effects of pentobarbital
on receptor function, however, were difficult to establish
from the data as presented in Fig. 6. To address this issue,
we plotted fluorescence and current responses versus pento-
barbital concentration using TMRM-a1L127Cb2 and
TMRM-a1b2K274Cg2 receptors; we selected these recep-
tors because they produced particularly clear FTMRM signals.
10 mM PB
ΔF
I
A B
5 sec
5 μA
1% 1%
5 sec
5
10
αβK274Cγ αβK274C
ΔF
I
mM PB
μA
FIGURE 5 Current and fluorescence traces in response
to a blocking concentration of pentobarbital (10 mM) on
(A) TMRM-a1b2K274Cg2 and (B) TMRM-a1b2K274C
receptors. Note prominent tail currents upon pentobarbital
removal.
FIGURE 6 Summary of fluorescence changes elicited by pentobarbital (PB) and GABA. Each bar represents mean percent change in fluorescence in
response to indicated ligands; error bars represent mean5 SE of n¼ 3–31 trials. Pentobarbital concentrations are 10 mM for blocking (tail current prominent),
300–800 mM for activating (current response with little or no tail current), and 50–100 mM for potentiating/modulating (little to no current). GABA concen-
trations are approximately EC90–99. *p < 0.05 for one-way ANOVA compared to wild-type (wt) and post hoc Dunnett’s test.
#This change was significant by
a t-test within a smaller data set (19).
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In this analysis, we attempted to establish parallels between
the concentration dependence of channel activation, channel
blockade, and FTMRM.
Fig. 7 compares plots of the concentration dependence of
pentobarbital-induced FTMRM, current (during pentobarbital
application), and block. Block was determined form the
tail current, as illustrated in the insets in each panel of
Fig. 7. The amplitude of the tail current (open squares)
was determined by fitting the current decay to an exponential
and extrapolating back in time to the start of drug removal.
Taking this extrapolated current as an estimate of the full
channel current in the absence of blockade (If) and the
current immediately before pentobarbital removal as the
current observed in the presence of blockade (Ib) allowed
us to calculate the extent of block. We also determined the
amplitude of the initial peak current before drug removal
(solid downward triangles). Current, extent of block, and
FTMRM were each normalized to their maxima and plotted
versus pentobarbital concentration (Fig. 7).
These plots revealed a close parallel between the concen-
tration dependence of the FTMRM change and receptor
blockade. By contrast, there was a clear disparity between
the concentration dependence of the FTMRM signal versus
the pentobarbital-induced receptor activation. These compar-
isons strongly support an association of the major component
of the pentobarbital-induced fluorescence change with its
blocking action. Because the concentration at which the
pentobarbital-induced current peaks falls well below the
concentration at which fluorescence saturates, the activated
state of the receptor induced by pentobarbital appears to be
associated with little, if any, change in fluorescence. The
parallel is not as clear for TMRM-a1b2K274Cg2 receptors
(Fig. 7 B), but this finding can be attributed to the fact that
low, potentiating pentobarbital concentrations induced
a small but significant fluorescence change (Fig. 4 B). The
nonzero fluorescence signal at the point < 100 mM, where
the current is zero, together with the increase in fluorescence
in parallel with the blockade indicate that this site undergoes
two distinct structural changes—one associated with poten-
tiation and the other with blockade.
Picrotoxin action on the upper part of M2
Because the label at K274C shows a strong fluorescence
change during block by pentobarbital, we examined the
structural changes induced by other important GABAA
receptor antagonists at this site. Picrotoxin is a GABAA
receptor antagonist that interacts with residues in M2 that
are deep within the ion channel, and it probably inhibits
current by both steric channel obstruction and allosteric
modulation (32–35). As expected, picrotoxin (100 mM
~IC99) strongly inhibited the current elicited by 1 mM
GABA in TMRM-a1b2K274Cg2 receptors, but the GABA-
induced fluorescence decrease remained unchanged
(Fig. 8). This experiment also showed that picrotoxin
application on its own induced no change in FTMRM. Thus,
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FIGURE 7 Changes in fluorescence parallel current
blockade by pentobarbital. Plot of fluorescence change
(DF, solid squares, broken line), current in the presence
of pentobarbital (downward solid triangles), and current
block (open squares). (A) TMRM-a1L127Cb2. (B)
TMRM-a1b2K274Cg2. Current response points were con-
nected by straight lines, whereas DF points were fitted
using least-squares regression to the Hill equation (see
Materials and Methods). All values were normalized to
the maximum for that measurement. Error bars represent
mean 5 SE of experiments in ~10 oocytes. The insets
show representative pentobarbital-induced current traces
including guides for our measurements of current in the
presence of pentobarbital (downward solid triangles) and
extrapolated tail current amplitude (open squares). The
decay of tail current was fitted to a single exponential (red), which was extrapolated to the time of buffer wash to estimate maximum current amplitude at
the time of buffer wash and block relief (see Materials and Methods).
2μA
1mM GABA
100 μM PTX
5 sec
2%
I
ΔF
2μA
5 sec
2%
A B
100 μM PTX
FIGURE 8 Picrotoxin blocks GABAA receptor channels
without altering fluorescence. Current (top) and fluores-
cence (bottom) change in TMRM-a1b2K274Xg2 receptors
challenged with EC90–99 GABA and 100 mM picrotoxin
(A) or picrotoxin alone (B).
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environment near b2K274C. Another GABAA receptor
antagonist SR95531 is a competitive inhibitor of GABA
binding and induces fluorescence changes in labels attached
to agonist-binding pocket residues in the a-subunit (19).
This compound at a concentration of 10 mM induced no
change in the fluorescence of TMRM-a1b2K274Cg2 recep-
tors (n ¼ 5; data not shown). Thus, residue 274 of the
b2-subunit responds differently when challenged with
different antagonists.
DISCUSSION
As better structural pictures of Cys-loop ligand-gated ion
channels emerge, the question of how allosteric modulators
and activators induce structural transitions between distinct
functional states comes into sharper focus. In this study, we
used site-specific fluorescent labels to probe transitions in
the GABAA receptor induced by pentobarbital; our results
demonstrate that functionally equivalent states induced by
the binding of pentobarbital and GABA have nonequivalent
structures. Furthermore, pentobarbital-induced channel block
triggers structural changes that are distinct from those seen
during activation and modulation. These structural changes
are also distinct from those elicited by other antagonists.
Distinctions between GABA- and pentobarbital-
induced conformational changes
GABA and pentobarbital both induce the opening of the
channel associated with the GABAA receptor, but these
two ligands bind to different sites (12). The action of pento-
barbital depends on residues in b-subunits toward the extra-
cellular end of M2 (13,14). Our study found that, among
homologous locations in M2 (240), the b2-subunit label—
but not the a1- or g2-subunit labels—demonstrated a fluores-
cence change in response to pentobarbital. Although we
could not distinguish between a direct interaction involving
pentobarbital and the b2K274C label and ligand-induced
protein movement at this site, our results provide further
support for the hypothesis that the extracellular end of M2
of a b-subunit has an important role in pentobarbital action.
GABA and pentobarbital appear to stabilize an open-state
channel structure with a similar single-channel conductance
(8,17) and similar chemical reactivity of residues at the 60
position in the channel-lining M2 helix (36).
In the extracellular N-terminus, GABA induced FTMRM
signals at positions a1L127C, a1E122C, b2L125C, and
b2P120C (19). We found that activation by pentobarbital
did not change the fluorescence of labels at these sites. The
FTMRM signals induced by pentobarbital at a1L127C and
b2L125C reflected blockade rather than activation, and
were opposite in sign to those elicited by GABA. When
GABA activates the GABAA receptor, the N-terminal
domains undergo a global, quasisymmetrical change in
Biophysical Journal 96(2) 499–509structure in which the homologous sites in the a- and b-
subunits undergo similar but unequal movements (19). Acti-
vation by pentobarbital occurs without a fluorescence change
at these same sites in the N-terminus. On this basis, we
conclude that pentobarbital and GABA both gate GABAA
receptor channels without inducing the same global struc-
tural changes in the N-terminus.
A residue near the extracellular end of M2 (b2K274C,
which is at the 240 position) also reports different movements
in response to GABA and pentobarbital. Potentiating
concentrations of pentobarbital elicited a fluorescence
change at this site in a1b2 receptors but not in a1b2g2 recep-
tors. GABA elicited a fluorescence change of the opposite
sign, but it did so in a1b2g2 receptors rather than in a1b2
receptors. Although the dependence of these changes on
subunit composition complicates the interpretation, the
results in a1b2K274Cg2 receptors offer an example where
GABA activation induces a movement near the top of M2,
whereas pentobarbital activation does not. Site-specific fluo-
rescent labeling studies in other Cys-loop ligand-gated chan-
nels (namely, the nicotinic receptor (20) and the glycine
receptor (21)) offer more examples of ligand-specific struc-
tural changes during activation. These studies (20,21) also
demonstrate that the sites exhibiting this behavior reside
near the extracellular end of M2. In the pre-M1 region, which
is quite close to the extracellular end of M2, GABA and
pentobarbital have different effects on the rates of modifica-
tion of introduced cysteines (37). A number of residues in the
N-terminus also respond to activation by pentobarbital by
changes in cysteine accessibility, and many of these changes
differ from those induced by GABA (27,38–41). Taken
together, these findings suggest that the structural mecha-
nisms underlying channel opening in Cys-loop ligand-gated
ion channels can differ substantially depending on the choice
of ligand used to trigger a response.
The present fluorescent labeling results together with the
above-cited cysteine accessibility study (37) identify a fairly
extensive part of the GABAA receptor, including the
N-terminus, pre-M1 region, and extracellular end of M2 of
the b2-subunit, where GABA and pentobarbital induce
different movements. However, deeper in the membrane,
the structural changes induced by these two ligands appear
to be more similar, as indicated by chemical reactivity (36)
and single-channel conductance (8,17). Rate-equilibrium
free energy analysis in the related nicotinic acetylcholine
receptor has indicated that the transduction of binding to
gating progresses through a sequence of coupled movements
of domains with roughly nanometer-sized dimensions. The
extracellular ligand-binding domain moves first, followed
by loops 2 and 7, which are located at the interface between
the extracellular domain and the transmembrane domain
(pre-M1); then the extracellular M2-M3 linker moves.
Finally, the transmembrane domains move, with the extra-
cellular and intracellular ends of M2 moving before the
middle (42,43). General anesthetics including pentobarbital
Structural Changes in the GABAA Receptor 507likely bind in a water-filled pocket in the upper transmem-
brane region of the GABAA receptor (13,14,44–47); this
region lies along the transduction pathway elucidated by
the rate-equilibrium free energy analysis in the nicotinic
receptor. Occupation of a site in this region could thus enable
pentobarbital to initiate channel opening at a deeper location,
triggering movements at the upper ends of the transmem-
brane domains that propagate toward the gate of the channel.
In this way, the transduction of pentobarbital binding to
channel gating could exhibit altered coupling to movements
in N-terminal domains.
We looked for conformational movements produced by
pentobarbital at modulating, activating, and blocking
concentrations, thereby probing three distinct modes of
action on the GABAA receptor. The sites to which pentobar-
bital binds to induce these various changes in receptor func-
tion are still unknown. With regard to the two positive effects
on receptor function, potentiation and activation, examining
the mechanisms by which other drugs exert similar actions
on the GABAA receptor provides a useful guide. Benzodiaz-
epines bind to a single site at the interface between the extra-
cellular domains of the a- and g-subunits. It is likely that
benzodiazepines both potentiate and activate the receptor
by an allosteric enhancement of channel opening by binding
to this one site (48–50). In contrast, neurosteroids likely acti-
vate the receptor and potentiate GABA-induced activity by
binding to two distinct sites among the transmembrane
domains (51). Thus, there are precedents for binding at both
a single site and multiple sites in the mediation of the related
actions of potentiation and activation. Ascertaining whether
barbiturates like pentobarbital target one or two sites on the
GABAA receptor for the two positive actions will require
further experiments.
The inﬂuence of a g-subunit
Labeled a1L127C and b2L125C mutants produced signifi-
cant fluorescence changes in response to pentobarbital in
a1b2 receptors but not in a1b2g2 receptors. Likewise, the
presence of the g2-subunit eliminated the fluorescence
change of TMRM-b2K274C that was induced by potentiating
concentrations of pentobarbital, but this subunit was neces-
sary for GABA-induced fluorescence changes in this mutant.
Previous work (19) has shown that the presence of the
g2-subunit alters the fluorescence responses of labels on other
subunits induced by both GABA and SR95531. Thus, we
have a number of examples demonstrating that the g2-subunit
influences ligand-induced structural changes in other
subunits. If the fluorescence changes were the result of direct
quenching by a ligand rather than a conformational change in
the protein, we would not expect the incorporation of another
subunit that has no direct role in ligand binding to have this
kind of an impact. GABAA receptors usually contain either
a g- or d- subunit, but recent work showingGABAA receptors
composed from a- and b-subunits in neurons (52) makes thequestion of how a g-subunit alters ligand-induced structural
transitions especially interesting. The presence of a g-subunit
thus alters the structural changes that drugs induce in other
subunits. In our structural models (Fig. 1), all of our labeled
sites are located at or near interfaces with other subunits,
and so subunit-subunit interactions could influence the struc-
tural changes within each subunit.
Distinctions between conformational changes
during block by pentobarbital and picrotoxin
Millimolar concentrations of pentobarbital inhibit the
GABAA receptor noncompetitively. Our fluorescence
measurements in combination with tail currents indicate
that the blocking action is actually detectable even before
the current starts to decline with increasing pentobarbital
concentration (Fig. 7). Single-channel recording has revealed
shorter mean open times and rapid flickering at increased
pentobarbital concentrations; this result is expected if pento-
barbital binds to the open state to induce channel block (8).
However, a kinetic model put forward to describe pentobar-
bital actions proposed that pentobarbital can bind to its
blocking site when the channel is closed (14); this model
supports the hypothesis that block by pentobarbital involves
more than a steric plugging of the pore. The pentobarbital-
binding site responsible for this antagonism has not been iden-
tified, and the stoichiometry remains controversial. One
single-channel study (8) suggested that the GABAA receptor
contains a single low-affinity pentobarbital channel-blocking
site, whereas another study (7) suggested that receptors
contain two or more blocking sites. Interestingly, our study
found large fluorescence changes in TMRM-a1L127C and
TMRM-b2K274C that closely tracked the time course and
concentration dependence of the blocking action of pentobar-
bital. The changes detected with N-terminal labels at
a1L127C and b2L125C indicate that this block induces an
allosteric transition that can extend a considerable distance
from the channel to the extracellular domain of the receptor.
These results thus provide strong evidence that pentobarbital
does more than simply occlude an open channel.
Picrotoxin, another well-established channel blocker of
the GABAA receptor, has been shown to interact with resi-
dues deep within the channel pore (32,35,53,54); studies
have also demonstrated that picrotoxin antagonism has an
allosteric component (35,55,56). Surprisingly, picrotoxin
had no discernible effect on the GABA-induced change in
fluorescence of TMRM-b2K274C in our study, even though
current was completely blocked. Thus, picrotoxin can block
the channel without inducing a structural change at this loca-
tion. Picrotoxin also failed to alter fluorescence signals in
labels at a1E122C and a1L127C (19), and a recent study
in the glycine receptor (21) reported that picrotoxin had no
effect on the glycine-induced fluorescence changes in a label
at the outer end of M2. In a fluorescent label study of the
N-terminus of the homooligomeric r1 GABAA receptor
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block the GABA-induced fluorescence change at one site,
slightly blocked the fluorescence change at another, and
completely blocked the fluorescence change at a third site.
Thus, picrotoxin can cause allosteric movements in this
particular GABAA receptor subtype, but the extent of these
movements appears to be limited.
Picrotoxin block of the channel did not change the fluores-
cence of TMRM-a1L127C and TMRM-b2K274C, whereas
pentobarbital block did. Inhibition by both SR95531 and
pentobarbital produced similar fluorescence changes in
labels at a1L127C (19). In TMRM-b2K274C, however,
pentobarbital induced a fluorescence change, whereas
SR95531 did not (data not shown). Furthermore, SR95531
did not induce fluorescence changes in any of the b2-subunit
labels tested here (the present results and (19)) but pentobar-
bital did (Fig. 3 C). Thus, these three different drugs can
block the GABAA receptor with different profiles of struc-
tural changes in the receptor protein. These patterns may
hold clues as to how diverse classes of drugs can antagonize
the same receptor by different mechanisms.
CONCLUSIONS
Fluorescent labels in the N-terminal agonist-binding domain
and in the extracellular end of the M2 membrane-spanning
segment have revealed that GABA, pentobarbital,
SR95531, and picrotoxin each induce different structural re-
arrangements in the GABAA receptor. The generation of an
open channel with the same conductance, however, does
not necessarily mean that the entire protein undergoes the
same structural change. Different forms of pharmacological
activation can elicit transitions to similar final open-channel
states in which other parts of the protein assume different
structures.Moreover, the extracellular end of theM2 segment
and the extracellular binding domain can undergo a variety of
conformational movements in response to channel activation
and channel block. By mapping out the conformational
movements that different drugs induce in different parts of
a protein, site-specific fluorescent labeling promises to
contribute a great deal to the elucidation of detailed molecular
mechanisms of drug action at GABAA receptors.
This work was supported by grant NS059854 from the National Institutes of
Health.
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